Literature DB >> 30612993

Chemotherapeutic options for the treatment of human trichomoniasis.

Erik Küng1, Ursula Fürnkranz1, Julia Walochnik2.   

Abstract

Trichomonas vaginalis is the causative agent of the most common non-viral sexually transmitted disease worldwide. The infection may be associated with severe complications, including infertility, preterm labour, cancer and an increased risk of human immunodeficiency virus (HIV) transmission. Treatment remains almost exclusively based on 5-nitroimidazoles, but resistance is on the rise. This article provides an overview of clinically evaluated systemic and topical treatment options for human trichomoniasis and summarises the current state of knowledge on various herbal, semisynthetic and synthetic compounds evaluated for their anti-Trichomonas efficacy in vitro.
Copyright © 2018 Elsevier B.V. and International Society of Chemotherapy. All rights reserved.

Entities:  

Keywords:  Drugs; Metronidazole resistance; STD; Trichomonas vaginalis; Trichomoniasis

Mesh:

Substances:

Year:  2018        PMID: 30612993     DOI: 10.1016/j.ijantimicag.2018.10.016

Source DB:  PubMed          Journal:  Int J Antimicrob Agents        ISSN: 0924-8579            Impact factor:   5.283


  7 in total

1.  Prevalence of double-stranded RNA virus in Trichomonas vaginalis isolated in Italy and association with the symbiont Mycoplasma hominis.

Authors:  Valentina Margarita; Alessandra Marongiu; Nicia Diaz; Daniele Dessì; Pier Luigi Fiori; Paola Rappelli
Journal:  Parasitol Res       Date:  2019-11-07       Impact factor: 2.289

2.  20S Proteasome as a Drug Target in Trichomonas vaginalis.

Authors:  Anthony J O'Donoghue; Betsaida Bibo-Verdugo; Yukiko Miyamoto; Steven C Wang; Justin Z Yang; Douglas E Zuill; Shoun Matsuka; Zhenze Jiang; Jehad Almaliti; Conor R Caffrey; William H Gerwick; Lars Eckmann
Journal:  Antimicrob Agents Chemother       Date:  2019-10-22       Impact factor: 5.191

Review 3.  Recent advances in the molecular biology of the protist parasite Trichomonas vaginalis.

Authors:  David Leitsch
Journal:  Fac Rev       Date:  2021-03-04

4.  Activation of the β-carbonic anhydrase from the protozoan pathogen Trichomonas vaginalis with amines and amino acids.

Authors:  Andrea Angeli; Linda J Urbański; Vesa P Hytönen; Seppo Parkkila; Claudiu T Supuran
Journal:  J Enzyme Inhib Med Chem       Date:  2021-12       Impact factor: 5.051

5.  Inhibition of the β-carbonic anhydrase from the protozoan pathogen Trichomonas vaginalis with sulphonamides.

Authors:  Linda J Urbański; Andrea Angeli; Vesa P Hytönen; Anna Di Fiore; Giuseppina De Simone; Seppo Parkkila; Claudiu T Supuran
Journal:  J Enzyme Inhib Med Chem       Date:  2021-12       Impact factor: 5.051

Review 6.  Application of Sol-Gels for Treatment of Gynaecological Conditions-Physiological Perspectives and Emerging Concepts in Intravaginal Drug Delivery.

Authors:  Ritu Thapa; Shila Gurung; Marie-Odile Parat; Harendra S Parekh; Preeti Pandey
Journal:  Gels       Date:  2022-02-08

Review 7.  Viruses of protozoan parasites and viral therapy: Is the time now right?

Authors:  Paul Barrow; Jean Claude Dujardin; Nicolas Fasel; Alex D Greenwood; Klaus Osterrieder; George Lomonossoff; Pier Luigi Fiori; Robert Atterbury; Matteo Rossi; Marco Lalle
Journal:  Virol J       Date:  2020-09-29       Impact factor: 4.099

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.